Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Current Deferred Tax Assets (2023 - 2026)

Sagimet Biosciences' Current Deferred Tax Assets history spans 4 years, with the latest figure at $402000.0 for Q1 2026.

  • Quarterly Current Deferred Tax Assets fell 35.68% to $402000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $402000.0 through Mar 2026, down 35.68% year-over-year, with the annual reading at $282000.0 for FY2025, 7.84% down from the prior year.
  • Current Deferred Tax Assets came in at $402000.0 for Q1 2026, up from $282000.0 in the prior quarter.
  • In the past five years, Current Deferred Tax Assets ranged from a high of $2.6 million in Q2 2023 to a low of $247000.0 in Q3 2025.
  • The 4-year median for Current Deferred Tax Assets is $323000.0 (2023), against an average of $638666.7.
  • Year-over-year, Current Deferred Tax Assets decreased 5.26% in 2024 and then plummeted 35.68% in 2026.
  • Sagimet Biosciences' Current Deferred Tax Assets stood at $323000.0 in 2023, then decreased by 5.26% to $306000.0 in 2024, then fell by 7.84% to $282000.0 in 2025, then skyrocketed by 42.55% to $402000.0 in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Current Deferred Tax Assets are $402000.0 (Q1 2026), $282000.0 (Q4 2025), and $247000.0 (Q3 2025).